Pharmacokinetics and pharmacodynamics of zolpidem after oral administration of a single dose in dogs

American Journal of Veterinary Research

Volumn 73, Issue 10, 2012, Pages 1650-1656

  Giorgi, Mario ^a   Portela, Diego Angel ^a   Breghi, Gloria ^a   Briganti, Angela ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ZOLPIDEM;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BRAIN DEPTH STIMULATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOG; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG HALF LIFE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; SEDATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; GABA-A RECEPTOR AGONISTS; HYPNOTICS AND SEDATIVES; MALE; PYRIDINES;

ANIMALIA; CANIS FAMILIARIS;

EID: 84867055625     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.73.10.1650     Document Type: Article

References (25)

1. What's wrong with prescribing hypnotics? Drugs Ther Bull 2004;42:89-93.
2. Morlock RJ, Tan M, Mitchell DY. Patient characteristics and patterns of drug use for sleep complaints in the United States: analysis of National Ambulatory Medical Survey data, 1997-2002. Clin Ther 2006;28:1044-1053.
3. Dawling S. Sedatives. In: Clinical management of poisoning and drug overdose. 3rd ed. Philadelphia: WB Saunders Co, 1998;581-607.
4. Holm KJ, Goa KL. Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs 2000;59:865-869.
5. Bloom FE. Neurotransmission and the central nervous system. In: Hardman JG, Limbird LE, Gilman AG, eds. The pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996;293-321.
6. Griebel G, Perrault G, Letang V, et al. New evidence that the pharmacological effects of benzodiazepine receptor ligands can be associated with activities at different BZ (omega) receptor subtypes. Psychopharmacology (Berl) 1999;146:205-213.
7. Dang A, Garg A, Rataboli PV. Role of zolpidem in the management of insomnia. CNS Neurosci Ther 2011;17:387-397.
8. Sherman BL, Papich MG. Drugs affecting animal behavior. In: Riviere JE, Papich MG, eds. Veterinary pharmacology and therapeutics. 9th ed. Ames, Iowa: Wiley-Blackwell, 2009;509-538.
9. Richardson JA, Gwaltney-Brant SM, Albretsen JC, et al. Clinical syndrome associated with zolpidem ingestion in dogs: 33 cases (January 1998-July 2000). J Vet Intern Med 2002;16:208-210.
10. Girard NM, Leece EA, Cardwell J, et al. The sedative effects of low-dose medetomidine and butorphanol alone and in combination intravenously in dogs. Vet Anaesth Analg 2010;37:1-6.
11. Giorgi M, Gavazza A, Yun HI. Quantification of zolpidem in canine plasma. Am J Anim Vet Sci 2012;7:36-41.
12. Gabrielsson J, Weiner D. Pharmacokinetic and pharmacodynamic data analysis: concepts and applications. 4th ed. Stockholm: Swedish Pharmaceutical Press, 2007.
13. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker Inc, 1982.
14. Durol AL, Greenblatt DJ. Analysis of zolpidem in human plasma by high-performance liquid chromatography with fluorescence detection: application to single-dose pharmacokinetic studies. J Anal Toxicol 1997;21:388-392.
15. Nirogi RV, Kandikere VN, Shrivasthava W, et al. Quantification of zolpidem in human plasma by high-performance liquid chromatography with fluorescence detection. Biomed Chromatogr 2006;20:1103-1138.
16. Salvà P, Costa J. Clinical pharmacokinetics and pharmacodynamics of zolpidem: therapeutic implications. Clin Pharmacokinet 1995;29:142-153.
17. Giorgi M, Del Carlo S, Saccomanni G, et al. Biopharmaceutical profile of tramadol in the dog. Vet Res Commun 2009;33:189-192.
18. Giorgi M, Yun H-I. Pharmacokinetics of mirtazapine and its main metabolites in Beagle dogs: a pilot study. Vet J 2012;192:239-241.
19. DeClerk AC, Bisserbe JC. Short-term safety profile of zolpidem: objective measures of cognitive effects. Eur Psychiatry 1997;12:15s-20s.
20. Diagnostic Classification Steering Committee of the America Sleep Disorders Association. International classification of sleep disorders-diagnostic and coding manual. Rochester, Minn: American Sleep Disorders Association, 1990.
21. Ellenhorn MJ. Sedative-hypnotic drugs. In: Ellenhorn's medical toxicology: diagnosis and treatment of human poisoning. 2nd ed. Baltimore: Williams & Wilkins, 1997;707-709.
22. Cubała WJ, Wiglusz M, Burkiewicz A, et al. Zolpidem pharmacokinetics and pharmacodynamics in metabolic interactions involving CYP3A: sex as a differentiating factor. Eur J Clin Pharmacol 2010;66:955.
23. Olubodun JO, Ochs HR, von Moltke LL, et al. Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men. Br J Clin Pharmacol 2003;56:297-304.
24. Cubała WJ, Landowski J, Wichowicz HM. Zolpidem abuse, dependence and withdrawal syndrome: sex as susceptibility factor for adverse effects. Br J Clin Pharmacol 2008;65:444-445.
25. Fraser DJ, Feyereisen R, Harlow GR, et al. Isolation, heterologous expression and functional characterization of a novel cytochrome P450 3A enzyme from a canine liver cDNA library. J Pharmacol Exp Therap 1997;283:1425-1432.